CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.

Saved in:
Bibliographic Details
Title: CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review.
Authors: Rankin AW; Division of Hematology, Oncology & Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH.; Department of Pediatrics, The Ohio State University, Columbus, OH., Myers RM; Cellular Therapy and Transplant Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA., Lamble AJ; Division of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA., Hsieh EM; Division of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA., Sankaran H; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Chen L; Cellular Therapy and Transplant Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA., Annesley C; Division of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA., DiNofia AM; Cellular Therapy and Transplant Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA., Grupp SA; Cellular Therapy and Transplant Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA., Pulsipher MA; Division of Hematology and Oncology, Primary Children's Hospital, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT., Dolan JG; Division of Hematology and Oncology, Primary Children's Hospital, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT., Bhojwani D; Division of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA., Gardner RA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN., Shah NN; National Cancer Institute/Center for Cancer Research, Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD., Rheingold SR; Cellular Therapy and Transplant Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Source: Blood advances [Blood Adv] 2026 May 26; Vol. 10 (10), pp. 3467-3479.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025018604